SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

被引：6

作者：

Sulkowski, M. ^{[1
]}

Bourliere, M. ^{[2
]}

Bronowicki, J. -P. ^{[3
]}

Streinu-Cercel, A. ^{[4
]}

Preotescu, L. ^{[4
]}

Asselah, T. ^{[5
]}

Pawlotsky, J. -M. ^{[6
]}

Shafran, S. ^{[7
]}

Pol, S. ^{[8
]}

Caruntu, F. A. ^{[4
]}

Mauss, S. ^{[9
]}

Larrey, D. ^{[10
]}

Haefner, C. ^{[11
]}

Datsenko, Y. ^{[11
]}

Stern, J. ^{[12
]}

Kubiak, R. ^{[11
]}

Steinmann, G. ^{[11
]}

机构：

[1] Johns Hopkins Univ, Dept Viral Hepatitis, Baltimore, MD USA

[2] Hop St Joseph, Marseille, France

[3] Hop Brabois, Vandoeuvre Les Nancy, France

[4] Prof Dr Matei Bals Inst Infect Dis 1, Bucharest, Romania

[5] Hop Beaujon, Clichy, France

[6] Hop Henri Mondor, F-94010 Creteil, France

[7] Univ Alberta, Edmonton, AB, Canada

[8] Hop Cochin, F-75674 Paris, France

[9] Ctr HIV & Hepatogastroenterol, Dusseldorf, Germany

[10] Hop St Eloi, Montpellier, France

[11] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany

[12] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA

来源：

JOURNAL OF HEPATOLOGY | 2010年 / 52卷

关键词：

D O I：

10.1016/S0168-8278(10)61191-9

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：S462 / S463

页数：2

共 50 条

[1] SVR AND PHARMACOKINETICS OF THE HCV PROTEASE INHIBITOR BI201335 WITH PEGIFN/RBV IN HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGIFN/RBV
Pol, S.
Berg, T.
Bonacini, M.
Schuchmann, M.
Lalezari, J.
Erhardt, A.
Bourliere, M.
Manns, M.
Stern, J. O.
Steinmann, G.
Yong, C. -L.
Scherer, J.
Boecher, W.
JOURNAL OF HEPATOLOGY, 2011, 54 : S486 - S486
[2] SILEN-C2: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO P/R
Sulkowski, M. S.
Bourliere, M.
Bronowicki, J. -P.
Streinu-Cercel, A.
Preotescu, L.
Asselah, T.
Pawlotsky, J. -M.
Shafran, S.
Pol, S.
Caruntu, F. A.
Mauss, S.
Larrey, D.
Haefner, C.
Datsenko, Y.
Stern, J. O.
Kubiak, R.
Boecher, W.
Steinmann, G.
JOURNAL OF HEPATOLOGY, 2011, 54 : S30 - S30
[3] THE ROLE OF FERRITIN AS A RESPONSE MARKER FOR ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH PEGINTERFERON ALFA-2A (PEGIFN) AND RIBAVIRIN (RBV)
Klass, Dietmar M.
Zizer, Eugen
Link, Ralph
Heyne, Renate
Lutz, Thomas
Schmidt, Wolfgang
Goesseringer, Roger
Alshuth, Ulrich
Mauss, Stefan
Hueppe, Dietrich
HEPATOLOGY, 2011, 54 : 868A - 868A
[4] SILEN-C1: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
Sulkowski, Mark S.
Ferenci, Peter
Emanoil, Ceausu
Asselah, Tarik
Caruntu, Florin
Lalezari, Jay
Bourliere, Marc
Mauss, Stefan
Grange, Jean-Didier
Berg, Thomas
Zeuzem, Stefan
Streinu-Cercel, Adrian
Wright, David
Jensen, Donald M.
Haefner, Carla
Datsenko, Yakiv
Stern, Jerry O.
Nehmiz, Gerhard
Steinmann, Gerhard
HEPATOLOGY, 2009, 50 (06) : 2A - 2A
[5] Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial
Sulkowski, Mark S.
Bourliere, Marc
Bronowicki, Jean-Pierre
Asselah, Tarik
Pawlotsky, Jean-Michel
Shafran, Stephen D.
Pol, Stanislas
Mauss, Stefan
Larrey, Dominique
Datsenko, Yakov
Stern, Jerry O.
Kukolj, George
Scherer, Joseph
Nehmiz, Gerhard
Steinmann, Gerhard G.
Boecher, Wulf O.
HEPATOLOGY, 2013, 57 (06) : 2155 - 2163
[6] VIROLOGICAL RESPONSE AND SAFETY OF BI 201335 PROTEASE INHIBITOR, PEGINTERFERON ALFA 2A AND RIBAVIRIN TREATMENT OF HCV GENOTYPE-1 PATIENTS WITH COMPENSATED LIVER CIRRHOSIS AND NON-RESPONSE TO PREVIOUS PEGINTERFERON RIBAVIRIN
Pol, Stanislas
Berg, Thomas
Bonacini, Maurizio
Schuchmann, Marcus
Lalezari, Jay
Erhardt, Andreas
Bourliere, Marc
Manns, Michael P.
Yong, Chan L.
Steinmann, Gerhard
Stern, Jerry O.
Scherer, Joe
Boecher, Wolf O.
HEPATOLOGY, 2009, 50 (06) : 10A - 11A
[7] Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegIFN/RBV) retreatment in patients with HCV-1 infection and prior non-response to pegIFN/RBV: One-year results
Afdhal, N.
O'Brien, C.
Godofsky, E.
Rodriguez-Torres, M.
Pappas, S. C.
Lawitz, E.
Pockros, P.
Sulkowski, M.
Jacobson, I.
Chao, G.
Knox, S.
Pietropaolo, K.
Brown, N. A.
JOURNAL OF HEPATOLOGY, 2007, 46 : S5 - S5
[8] Lack of effect of ribavirin (RBV) on early HCV kinetics when combined with peginterferon alfa-2a (pIFN)
Lutchman, GA
Neumann, A
Ghany, M
Heller, T
Park, Y
Bozorg, B
Liang, TJ
Hoofnagle, J
GASTROENTEROLOGY, 2004, 126 (04) : A668 - A668
[9] SILEN-C3: TREATMENT FOR 12 OR 24 WEEKS WITH BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAiVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION
Dieterich, Douglas
Asselah, Tarik
Guyader, Dominique
Berg, Thomas
Ceausu, Emanoil
Preotescu, Liliana
Schuchmann, Marcus
Mauss, Stefan
Ratziu, Vlad
Ferenci, Peter
Larrey, Dominique G.
Maieron, Andreas
Biermer, Michael
Stern, Jerry O.
Scherer, Joe
Kubiak, Rene
Boecher, Wulf O.
HEPATOLOGY, 2011, 54 : 378A - 378A
[10] SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
Sulkowski, M. S.
Ceasu, E.
Asselah, T.
Caruntu, F. A.
Lalezari, J.
Ferenci, P.
Streinu-Cercel, A.
Fainboim, H.
Tanno, H.
Preotescu, L.
Leggett, B.
Bessone, F.
Mauss, S.
Stern, J. O.
Haefner, C.
Datsenko, Y.
Nehmiz, G.
Boecher, W.
Steinmann, G.
JOURNAL OF HEPATOLOGY, 2011, 54 : S27 - S27

← 1 2 3 4 5 →